Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093...
HKG: 3692
Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has assumed exclusive licensing rights from...
Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug...
Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) has announced that its investigational antibody-drug conjugate (ADC),...
Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...
Hansoh Pharma Reports 22.6% Revenue Growth in 2025, Driven by Oncology and $4.54B in Global Licensing Deals
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced robust 2025 financial results, with RMB 15.028...
Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs – HS‑20152 and HS‑10587 Enter Clinical Trials in Rare Disease and Oncology
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have...
Hansoh Pharma’s Mirdametinib Plus Almonertinib NDA Accepted by NMPA – Dual‑Target Combination for EGFR‑Mutant NSCLC
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that China’s National Medical Products Administration (NMPA) has...
Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has...
Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical...
Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones
Jiangsu Hansoh Pharmaceutical Co. Ltd. (HKG: 3692) entered into an exclusive license, collaboration, and distribution...
Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients...
Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC
China‑based Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced today that it has filed a New Drug Application...
Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110
Hansoh Pharmaceutical Group (HKG: 3692) today announced a licensing agreement with Roche (SWX: ROG, OTCMKTS:...
Hansoh Pharma Secures Second FDA‑Approved Indication for Inebilizumab in IgG4‑Related Disease
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its inebilizumab injection has received...
Hansoh’s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six...
Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...
Hansoh Pharmaceutical Partners with Regeneron for HS-20094 Global Rights
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with Regeneron Pharmaceuticals...
Hansoh Pharma Gains NMPA Clinical Approvals for HS-10510, HS-10542, and HS-20118
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received separate clinical...
Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...